Latest news with #NASDAQ-100Index
Yahoo
6 days ago
- Business
- Yahoo
High Growth US Tech Stocks To Watch In June 2025
The United States market has shown a positive trend, rising 1.3% over the last week and up 13% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability within their sectors. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ Travere Therapeutics 26.41% 64.47% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.18% 60.67% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Alnylam Pharmaceuticals 23.64% 60.71% ★★★★★★ Ascendis Pharma 35.14% 60.18% ★★★★★★ Lumentum Holdings 22.86% 103.97% ★★★★★★ Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Shopify Inc. is a commerce technology company that offers tools for businesses of all sizes to start, scale, market, and operate across various regions globally, with a market cap of $143.05 billion. Operations: Shopify generates revenue primarily from its Internet Software & Services segment, amounting to $9.38 billion. The company operates across multiple regions, providing technology solutions for businesses to manage and grow their operations. Shopify, recently added to the NASDAQ-100 Index, has shown a robust performance with significant strategic partnerships enhancing its e-commerce platform. The company's revenue growth at 17.3% annually outpaces the US market average of 8.6%, and earnings are expected to surge by 21.1% per year. Recent alliances, like with Sovos for automated sales tax filings and Manhattan Associates for improved order management, underscore Shopify's commitment to streamlining merchant operations and expanding service offerings. Despite facing legal challenges from Sezzle alleging anticompetitive practices, Shopify continues to innovate; notably integrating to boost its enterprise-grade promotions capabilities—indicative of its aggressive expansion in high-growth tech sectors. Click here and access our complete health analysis report to understand the dynamics of Shopify. Understand Shopify's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sandisk Corporation is a company that specializes in the development, manufacturing, and sale of data storage devices and solutions utilizing NAND flash technology across various regions worldwide, with a market capitalization of approximately $6.08 billion. Operations: Sandisk focuses on the development, manufacturing, and sale of data storage devices using NAND flash technology. The company's primary revenue stream comes from its Computer Storage Devices segment, generating $7.21 billion. Sandisk, amidst a volatile market, has demonstrated resilience with a revenue increase of 10.7% over the past year and an impressive forecast for earnings growth at 108.72% annually. Recent strategic moves include a substantial follow-on equity offering raising $713.58 million, positioning it well for future expansions despite recent impairment charges of $1.83 billion in goodwill reflecting cautious market conditions. These financial maneuvers underscore Sandisk's proactive approach in navigating tech sector challenges while gearing up for profitability, anticipated robustly within the next three years. Delve into the full analysis health report here for a deeper understanding of Sandisk. Assess Sandisk's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Synopsys, Inc. specializes in electronic design automation software for designing and testing integrated circuits, with a market capitalization of $78.26 billion. Operations: The company generates revenue primarily from two segments: Design IP, contributing $1.90 billion, and Design Automation, accounting for $4.32 billion. Synopsys, a leader in silicon-to-systems design solutions, is making significant strides in the tech sector with its recent collaboration with Plug and Play Semiconductors. This partnership aims to democratize access to advanced design tools for startups, potentially accelerating chip innovation and reducing entry barriers. In a notable development on June 5, 2025, Synopsys also partnered with Keysight Technologies to introduce an AI-powered RF design migration flow, enhancing wireless circuit designs' efficiency and speed. These initiatives not only strengthen Synopsys's position in semiconductor innovation but also highlight its commitment to integrating AI technologies to streamline processes and boost productivity within the industry. Get an in-depth perspective on Synopsys' performance by reading our health report here. Gain insights into Synopsys' historical performance by reviewing our past performance report. Access the full spectrum of 230 US High Growth Tech and AI Stocks by clicking on this link. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHOP SNDK and SNPS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Shopify (NasdaqGS:SHOP) Added To NASDAQ-100 Index Following Positive Developments
Shopify recently gained attention with its addition to the NASDAQ-100 Index on May 19, a move that likely bolstered its standing among investors. Over the past month, the company's shares rose by about 30%, a significant contrast to the broader market's smaller growth. This jump was potentially influenced further by a strategic three-year partnership with Global-e Online, announced in mid-May, which aims to enhance international e-commerce operations. Despite a reported net loss in financial performance, these strategic moves seemed to reinforce investor confidence, contributing to the company's robust share price growth. You should learn about the 2 warning signs we've spotted with Shopify. AI is about to change healthcare. These 21 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The addition of Shopify to the NASDAQ-100, alongside its new alliance with Global-e Online, might serve as a crucial catalyst for its broader growth strategy. Despite recent gains, Shopify's share value stands at a discount of 5.08% to the consensus price target of US$114.64. This relationship implies potential upside, should the strategic developments bolster their revenue and earnings forecasts effectively. Investors appear to be supportive of the initiatives aiming to enhance international e-commerce operations and expand Shopify's influence in the global market. Over the past three years, Shopify's total return was very large, indicating a robust long-term performance despite recent volatility. For context, this impressive growth contrasts with a more recent one-year performance where Shopify outperformed the US IT industry, which grew by 28.9%. This trend highlights Shopify's capacity to sustain momentum amidst competitive market pressures. The revenue and earnings forecasts reflect expansion ambitions, projecting annual growth rates exceeding US market averages. However, these optimistic forecasts depend on successful execution of initiatives like AI investments and broader strategic partnerships. Aligning these outcomes with the current price target suggests that despite the company's aggressive growth objectives, investor expectations remain tempered by potential execution risks. Gain insights into Shopify's outlook and expected performance with our report on the company's earnings estimates. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SHOP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
15-05-2025
- Business
- Yahoo
Should Invesco QQQ (QQQ) Be on Your Investing Radar?
If you're interested in broad exposure to the Large Cap Growth segment of the US equity market, look no further than the Invesco QQQ (QQQ), a passively managed exchange traded fund launched on 03/10/1999. The fund is sponsored by Invesco. It has amassed assets over $323.52 billion, making it the largest ETFs attempting to match the Large Cap Growth segment of the US equity market. Companies that fall in the large cap category tend to have a market capitalization above $10 billion. Overall, they are usually a stable option, with less risk and more sure-fire cash flows than mid and small cap companies. While growth stocks do boast higher than average sales and earnings growth rates, and they are expected to grow faster than the wider market, investors should note these kinds of stocks have higher valuations. Also, growth stocks are a type of equity that carries more risk compared to others. They are likely to outperform value stocks in strong bull markets but over the longer-term, value stocks have delivered better returns than growth stocks in almost all markets. Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Annual operating expenses for this ETF are 0.20%, making it one of the cheaper products in the space. It has a 12-month trailing dividend yield of 0.58%. It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Information Technology sector--about 51.30% of the portfolio. Telecom and Consumer Discretionary round out the top three. Looking at individual holdings, Apple Inc (AAPL) accounts for about 8.49% of total assets, followed by Microsoft Corp (MSFT) and Nvidia Corp (NVDA). The top 10 holdings account for about 48.47% of total assets under management. QQQ seeks to match the performance of the NASDAQ-100 Index before fees and expenses. The Nasdaq-100 Index includes 100 of the largest domestic and international nonfinancial companies listed on the Nasdaq Stock Market based on market capitalization. The ETF has gained about 1.60% so far this year and is up about 16.98% in the last one year (as of 05/15/2025). In the past 52-week period, it has traded between $416.06 and $539.52. The ETF has a beta of 1.17 and standard deviation of 23.44% for the trailing three-year period, making it a medium risk choice in the space. With about 101 holdings, it effectively diversifies company-specific risk. Invesco QQQ carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, QQQ is a sufficient option for those seeking exposure to the Style Box - Large Cap Growth area of the market. Investors might also want to consider some other ETF options in the space. The iShares Russell 1000 Growth ETF (IWF) and the Vanguard Growth ETF (VUG) track a similar index. While iShares Russell 1000 Growth ETF has $106.03 billion in assets, Vanguard Growth ETF has $163.72 billion. IWF has an expense ratio of 0.19% and VUG charges 0.04%. While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco QQQ (QQQ): ETF Research Reports Apple Inc. (AAPL) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report iShares Russell 1000 Growth ETF (IWF): ETF Research Reports Vanguard Growth ETF (VUG): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-04-2025
- Business
- Yahoo
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month
Recent legal challenges have put Moderna in a spotlight, as Genevant Sciences and Arbutus Biopharma Corporation have filed lawsuits alleging patent infringements related to lipid nanoparticle technology across numerous countries, affecting products like Spikevax®. This ongoing legal tussle has impacted investor sentiment, contributing to the company's share price decline of 8% over the month. Compounding this, general market trends showed volatility with a 3% decline. Despite tech gains, broader market uncertainties, including tariffs and economic concerns, have weighed on stocks like Moderna, which hit a five-year low amid these broader market trends. Buy, Hold or Sell Moderna? View our complete analysis and fair value estimate and you decide. Trump has pledged to "unleash" American oil and gas and these 20 US stocks have developments that are poised to benefit. Over the last five years, Moderna's total shareholder return, including share price and dividends, amounted to an 18.16% decline. In a challenging landscape, legal and regulatory hurdles have played a significant role. One major event was the March 2025 lawsuits filed by Genevant Sciences and Arbutus Biopharma Corporation over patent infringements related to Moderna's lipid nanoparticle technology. Financial performance, notably in 2024, saw revenue fall to US$3.24 billion from US$6.85 billion in 2023, highlighting the drop in COVID-related product sales. The company's exclusion from the NASDAQ-100 Index in December 2024 further exemplified declining investor confidence. Efforts at diversification, such as Health Canada's approval of the mRESVIA vaccine for adults, signal positive potential. However, inventory write-downs and a net loss of $3.6 billion in 2024 underscore continuing challenges. Over the past year, Moderna underperformed both the U.S. market and Biotech industry, with the market posting a 6.1% increase and the Biotech industry experiencing an 11.9% decline. Our valuation report here indicates Moderna may be overvalued. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:MRNA. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
31-03-2025
- Business
- Yahoo
MicroStrategy (NasdaqGS:MSTR) Gains 13% Over Last Month With New US$722M Offering
MicroStrategy recently declared a preferred dividend of $1.24 per share and appointed new co-lead underwriters for its $722 million fixed-income offering. Despite the broader market experiencing declines, including the S&P 500 and Nasdaq index posting their worst month since 2022, MicroStrategy's shares rose by 13% last month. This contrasts the broader tech sector that saw declines amid economic concerns and new tariff announcements. The company's share performance may be partly attributable to its strategic financial moves in a challenging market, supporting investor confidence despite broader market volatility. We've identified 3 risks with MicroStrategy (at least 1 which is significant) and understanding the impact should be part of your investment process. AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. MicroStrategy's total shareholder return over the past five years was an extremely large 2394.27%. This remarkable performance contrasts with its current financial setbacks, as the company exceeded the broader US market, which saw a much smaller return of 5.8% in the past year. Several key initiatives have influenced this long-term return. Notably, in March 2024, MicroStrategy announced plans to acquire more Bitcoin through proceeds from a US$600 million offering, embracing cryptocurrency as a part of its balance sheet strategy. Additionally, its recent inclusion in the NASDAQ-100 Index in December 2024 may have also bolstered investor interest. Product innovation has played a role too, with continuous updates to the MicroStrategy ONE platform, such as the incorporation of generative AI features in January 2025. Despite challenges, such as increasing net losses and shareholder dilution over the past year, these factors have likely maintained investor confidence in the company's future outlook, supporting its long-term return. Examine MicroStrategy's earnings growth report to understand how analysts expect it to perform. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:MSTR. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
